Ann Clin Microbiol.  2022 Sep;25(3):85-90. 10.5145/ACM.2022.25.3.3.

Antimicrobial susceptibility patterns and clinical characteristics of Corynebacterium striatum cases from 2018 to 2021

• Choi I
• Lee Y

• KMID: 2533950
• DOI: http://doi.org/10.5145/ACM.2022.25.3.3

Abstract

Background
Corynebacterium striatum is part of the normal flora of the skin, oral cavity, and intestine. However, it can be a pathogen causing endocarditis, pneumonia, arthritis, and meningitis occasionally. We evaluated the clinical features and antimicrobial susceptibility pattern of C. striatum cases.
Methods
Patients infected with C. striatum, who consulted infectious disease physicians and were admitted to Hanyang University hospital between January 2018 and January 2021, were enrolled for an antimicrobial susceptibility test (AST). We reviewed medical records of selected patients for information on diagnosis, specimen types, and antibiotics used before and after AST. AST was performed using E-test and interpreted according to the Clinical and Laboratory Standards Institute M45 guidelines.
Results
A total of 23 cases were evaluated, and average age of patients was 58.5 years. Ten cases were diagnosed sepsis. Eight cases were complicated with cancer, and five cases had wound infections. Four cases were treated with vancomycin prior to AST; in 13 cases, antibiotics were switched to vancomycin after AST. Resistance rates were highest for ciprofloxacin (93.3%), which was followed by cefotaxime (92.3%), penicillin G (87.0%), erythromycin (87.0%), trimethoprim/sulfamethoxazole (78.3%), and meropenem (76.5%).
Conclusion
The patients infected by C. striatum were old and immunosuppressed, while many had cancer. Since C. striatum shows resistance to most drugs except vancomycin, we should consider conducting AST prior to antibiotic treatment.

Keyword

Antimicrobial susceptibility pattern; Corynebacterium striatum; Multi-drug resistance

Figure

• 

  Fig. 1. 3 weeks and 16 weeks post-vaccination antibody titer by vaccine groups, (A) Pfizer vaccine group (B) AstraZeneca vaccine group.

Reference

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-3. .

2. Mahase E. Covid-19: Pfizer and BioNTech submit vaccine for US authorisation. BMJ 2020;371:m4552. .

3. Knoll MD and Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 2021;397:72-4. .

4. He X, He C, Hong W, Zhang K, Wei X. The challenges of COVID-19 Delta variant: prevention and vaccine development. MedComm 2021;2:846-54. .

5. Kang SJ, Kim S, Park KH, Jung SI, Shin MH, Kweon SS, et al. Successful control of COVID-19 outbreak through tracing, testing, and isolation: lessons learned from the outbreak control efforts made in a metropolitan city of South Korea. J Infect Public Health 2021;14:1151-4. .

6. Sung H, Roh KH, Hong KH, Seong MW, Ryoo N, Kim HS, et al. COVID-19 molecular testing in Korea: practical essentials and answers from experts based on experiences of emergency use authorization assays. Ann Lab Med 2020;40:439-47. .

7. FDA. COVID-19 Vaccines. https://www.fda.gov/emergency-preparedness-and-response/ coronavirus-disease-2019-covid-19/covid-19-vaccines [Online] (last visited on 15 September 2022). .

8. MFDS. COVID-19 Vaccines. https://www.mfds.go.kr/vaccine_covid19.jsp# [Online] (last visited on 15 September 2022). .

9. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92. .

10. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. Clin Chem 2020;66:1538-47. .

11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15. .

12. Emanuel EJ, Persad G, Kern A, Buchanan A, Fabre C, Halliday D, et al. An ethical framework for global vaccine allocation. Science 2020;369:1309-12. .

13. Grauer J, Lowen H, Liebchen B. Strategic spatiotemporal vaccine distribution increases the survival rate in an infectious disease like Covid-19. Sci Rep 2020;10:21594. .

14. Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020;62:103101. .

15. The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of f ive immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020;20:1390-400. .

16. Dimeglio C, Herin F, Martin-Blondel G, Miedouge M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect 2022;84:248-88. .